These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 1417374

  • 1. Stroke complicating acute myocardial infarction. A meta-analysis of risk modification by anticoagulation and thrombolytic therapy.
    Vaitkus PT, Berlin JA, Schwartz JS, Barnathan ES.
    Arch Intern Med; 1992 Oct; 152(10):2020-4. PubMed ID: 1417374
    [Abstract] [Full Text] [Related]

  • 2. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.
    GUSTO investigators.
    N Engl J Med; 1993 Sep 02; 329(10):673-82. PubMed ID: 8204123
    [Abstract] [Full Text] [Related]

  • 3. Percutaneous transluminal coronary angioplasty versus thrombolysis in acute myocardial infarction: a meta-analysis.
    Vaitkus PT.
    Clin Cardiol; 1995 Jan 02; 18(1):35-8. PubMed ID: 7704983
    [Abstract] [Full Text] [Related]

  • 4. The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico II (GISSI-2), and The International Study Group.
    Maggioni AP, Franzosi MG, Santoro E, White H, Van de Werf F, Tognoni G.
    N Engl J Med; 1992 Jul 02; 327(1):1-6. PubMed ID: 1598096
    [Abstract] [Full Text] [Related]

  • 5. New developments in thrombolytic therapy.
    Collen D, Gold HK.
    Adv Exp Med Biol; 1990 Jul 02; 281():333-54. PubMed ID: 2129372
    [Abstract] [Full Text] [Related]

  • 6. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators.
    Weaver WD, White HD, Wilcox RG, Aylward PE, Morris D, Guerci A, Ohman EM, Barbash GI, Betriu A, Sadowski Z, Topol EJ, Califf RM.
    JAMA; 1996 Mar 13; 275(10):777-82. PubMed ID: 8598594
    [Abstract] [Full Text] [Related]

  • 7. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
    Mak KH, Moliterno DJ, Granger CB, Miller DP, White HD, Wilcox RG, Califf RM, Topol EJ.
    J Am Coll Cardiol; 1997 Jul 13; 30(1):171-9. PubMed ID: 9207639
    [Abstract] [Full Text] [Related]

  • 8. Stroke in patients treated with thrombolytic therapy for acute myocardial infarction. The thrombosis in myocardial infarction clinical trial and a review of placebo-controlled trials.
    Price TR.
    Stroke; 1990 Nov 13; 21(11 Suppl):III8-9. PubMed ID: 2122557
    [Abstract] [Full Text] [Related]

  • 9. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.
    Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Armstrong PW, Barbash G, White H, Simoons ML, Nelson CL.
    N Engl J Med; 1995 May 25; 332(21):1418-24. PubMed ID: 7723799
    [Abstract] [Full Text] [Related]

  • 10. Effect of thrombolytic therapy on the evolution of significant mitral regurgitation in patients with a first inferior myocardial infarction.
    Leor J, Feinberg MS, Vered Z, Hod H, Kaplinsky E, Goldbourt U, Truman S, Motro M.
    J Am Coll Cardiol; 1993 Jun 25; 21(7):1661-6. PubMed ID: 8496534
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. ISIS-3 and GISSI-2: no survival advantage with tissue plasminogen activator over streptokinase, but a significant excess of strokes with tissue plasminogen activator in both trials.
    Collins R, Peto R, Parish S, Sleight P.
    Am J Cardiol; 1993 May 01; 71(12):1127-30. PubMed ID: 8475887
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review.
    Weaver WD, Simes RJ, Betriu A, Grines CL, Zijlstra F, Garcia E, Grinfeld L, Gibbons RJ, Ribeiro EE, DeWood MA, Ribichini F.
    JAMA; 1997 Dec 17; 278(23):2093-8. PubMed ID: 9403425
    [Abstract] [Full Text] [Related]

  • 16. Strokes, statistics and sophistry in trials of thrombolysis for acute myocardial infarction.
    Sobel BE, Collen D.
    Am J Cardiol; 1993 Feb 15; 71(5):424-7. PubMed ID: 8430631
    [No Abstract] [Full Text] [Related]

  • 17. Thrombolytic therapy with streptokinase and tissue plasminogen activator in a patient with suspected acute myocardial infarction: A decision analysis.
    Hiatt MD.
    Cardiology; 1999 Feb 15; 91(4):243-9. PubMed ID: 10545680
    [Abstract] [Full Text] [Related]

  • 18. Safe use of thrombolysis in the elderly.
    Wittry MD, Thornton TA, Chaitman BR.
    Geriatrics; 1989 Nov 15; 44(11):28-30, 33-6. PubMed ID: 2509296
    [Abstract] [Full Text] [Related]

  • 19. Selection factors for the use of thrombolytic treatment in acute myocardial infarction: a population based study of current practice in the United Kingdom. The European Secondary Prevention Study Group.
    Ketley D, Woods KL.
    Br Heart J; 1995 Sep 15; 74(3):224-8. PubMed ID: 7547014
    [Abstract] [Full Text] [Related]

  • 20. Comparison of "accelerated" tissue plasminogen activator with streptokinase for treatment of suspected myocardial infarction.
    Kellett J, Clarke J.
    Med Decis Making; 1995 Sep 15; 15(4):297-310. PubMed ID: 8544674
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.